Tianshui Zhongxing Bio-technology Co Ltd

Tianshui Zhongxing Bio-technology Co Ltd maintains a debt-to-equity ratio of 0.82, indicating a moderate reliance on debt financing. The company's liquidity is assessed as medium, with a current ratio of 2.38, suggesting it can cover its short-term liabilities with its current assets. However, the company's free cash flow is negative at -94.49 million CNY, which may signal pressure on liquidity and the need for external financing or operational improvements. The company's profitability is reflected in a return on equity (ROE) of 9.5% and a return on assets (ROA) of 4.73%. These figures are in line with the industry's preferred metrics, which emphasize asset efficiency and capital returns. The operating margin, calculated as operating income of 335.10 million CNY on revenue of 2.10 billion CNY, is 15.98%, which is a strong indicator of cost control and pricing power. The company's revenue is primarily derived from a single business segment, with no disclosed geographic diversification. This concentration may expose the company to regional economic or regulatory risks. The lack of segmental or geographic breakdown in the financial data suggests a need for further transparency in the company's reporting. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the current or next fiscal year. The capital expenditure of -551.55 million CNY indicates a significant investment in long-term assets, which may support future growth but could also strain short-term liquidity. The company's risk profile includes a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in meeting long-term obligations without additional financing. The dilution risk is low, with no significant changes in shares outstanding between basic and diluted figures. Recent events, including analyst estimates and earnings performance, indicate a generally positive outlook. The mean recommendation from analysts is 1.50, with one strong buy and one buy rating. The last actual EPS of 0.89 CNY slightly exceeded the mean estimate of 0.88 CNY, suggesting the company is meeting or slightly outperforming expectations.